Subtype
Blood Vessel Neoplasm
CI-CAN-00000567Explore in graph →
Non-malignant50 active trials4 approved drugs8 evidence items
- NCIt
- C7387
Loading cancer entity…
Subtype
CI-CAN-00000567Explore in graph →
Clinical trials
292 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006518 | Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer | recruiting | — | 1,029 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03300830 | Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease | recruiting | — | 280 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT06798363 | Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma | recruiting | Phase 2 / Phase 3 | 32 | West China HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06898203 | Precision Imaging to Evaluate Kaposi Sarcoma(PRIME-KS) | recruiting | N/A | 180 | Washington University School of MedicineOTHER | 2 | Sep 21, 2026 | clinicaltrials |
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06375122 | Natural History Study of Kaposi Sarcoma | recruiting | — | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | recruiting | Phase 2 | 18 | Varun Monga, MBBSOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07308886 | Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07656909 | Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP | recruiting | Phase 2 / Phase 3 | 76 | Yi JiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07104331 | SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma | recruiting | Phase 2 | 41 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05983159 | A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations(TARGET-VM) | recruiting | Phase 2 | 50 | Murdoch Childrens Research InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06445166 | Propranolol for the Treatment of Kaposi Sarcoma in Adults | recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06408441 | The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)(EHE) | recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 10 | Apr 3, 2026 | clinicaltrials |
| NCT06751355 | Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial(PRIME-KS) | recruiting | — | 30 | Washington University School of MedicineOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04305691 | Trial of Ixazomib for Kaposi Sarcoma | recruiting | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06715579 | Cardiac Angiosarcoma International Registry(CAIR) | recruiting | — | 500 | Immune Oncology Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07418294 | Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study | recruiting | — | 400 | Yonsei UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04055220 | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas(REGOSTA) | recruiting | N/A | 168 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06004011 | AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) | recruiting | N/A | 4,100 | ImplenomicsOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06375941 | Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars(ProStars) | recruiting | — | 250 | Italian Sarcoma GroupNETWORK | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06541652 | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers(FFCD-2205) | recruiting | — | 150 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06214767 | Study on Treatment Decision-Making and Prognostic Follow-Up for Untreated Cerebral Cavernous Malformations | recruiting | — | 1,200 | Beijing Tiantan HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05477680 | Intraoperative Brain Shift Calculation Study(BRASH) | recruiting | N/A | 100 | Sklifosovsky Institute of Emergency CareOTHER_GOV | 1 | May 16, 2025 | clinicaltrials |
| NCT05484245 | Sonography-guided Resection of Brain Mass Lesions(SOMALI) | recruiting | N/A | 100 | Sklifosovsky Institute of Emergency CareOTHER_GOV | 1 | May 16, 2025 | clinicaltrials |
| NCT06915649 | Exploration and Evaluation of Amygdalo-Hippocampectomy According to Prof. Coubes' Technique: An Anatomical, Clinical, and Educational Approach | recruiting | — | 3,504 | University Hospital, MontpellierOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06056635 | A Prospective Study on the Role of Karl Storz Curved and Straight Fetoscopes (11508AAK and 11506AAK) for Fetoscopic Intrauterine Procedures | recruiting | N/A | 50 | Boston Children's HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05424016 | Propranolol and Von Hippel-Lindau Disease(PRO-HEB) | recruiting | N/A | 85 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01873131 | A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn | recruiting | N/A | 126 | Massachusetts General HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05961761 | Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients(PROPANE) | recruiting | Phase 2 | 80 | Niels JunkerOTHER | 3 | Jul 27, 2023 | clinicaltrials |
| NCT04076449 | Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy(CRESS) | recruiting | — | 200 | yuanli ZhaoOTHER | 1 | Sep 4, 2019 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials